Sublocade® 300mg shortage update – March 2022

“Unconstrained supplies of US-branded Sublocade® 300mg available for deliveries from week commencing 21st March.”

Sublocade® manufacturer, Indivior, has advised positive changes to the issues with supply of Sublocade 300mg strength under S19A conditions. Please refer to the official advice from Indivior, available here. Particular attention should be paid to the reduced out-of-refrigeration shelf life of the US-branded version compared to the Australian registered version (7 days cf. 28 days).

Support and advice on managing patients during this shortage is available from the manufacturer, Indivior, as well as via your local PABN, including specialist clinical support, where available.

Find your local PABN contact here.

Contact Indivior via telephone 02 9025 0200 or email

Practice Nurse Education Series

Videos now available here


The Pharmacotherapy Area-Based Networks have worked closely with the Victorian Department of Health and Human Services, key stakeholders and providers to develop a series of guides for responding to the challenges of providing pharmacotherapy services during the COVID-19 pandemic. Find an overview with links to the guides on our new, dedicated COVID-19 page.

Get the guidelines now.

Scheduled events

Submit an event  

Upcoming Opioid ECHO sessions

More information and registration

We've updated our essential resources page with new links, files and a desktop pack.